La Jolla Pharmaceutical (LJPC) Misses Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LJPC Hot Sheet
Price: $6.22 --0%
Financial Fact:
Loss from operations: -15.62M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Loss from operations: -15.62M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
La Jolla Pharmaceutical (NASDAQ: LJPC) reported Q4 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $234 thousand versus the consensus estimate of $210 thousand.
For earnings history and earnings-related data on La Jolla Pharmaceutical (LJPC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- MoonLake Immunotherapeutics (MLTX) Misses Q3 EPS by 15c
- Fidelity National Information Services, Inc. (FIS) Tops Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
